California Public Employees Retirement System Sells 1,119 Shares of Heron Therapeutics Inc (NASDAQ:HRTX)

California Public Employees Retirement System lowered its holdings in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 1.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 69,150 shares of the biotechnology company’s stock after selling 1,119 shares during the period. California Public Employees Retirement System’s holdings in Heron Therapeutics were worth $1,690,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Parallel Advisors LLC boosted its position in Heron Therapeutics by 247.4% during the 1st quarter. Parallel Advisors LLC now owns 1,685 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 1,200 shares during the period. Pearl River Capital LLC boosted its position in Heron Therapeutics by 1,900.0% during the 1st quarter. Pearl River Capital LLC now owns 2,000 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,900 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Heron Therapeutics by 24.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,747 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 929 shares during the period. SG Americas Securities LLC purchased a new stake in Heron Therapeutics during the 1st quarter valued at $151,000. Finally, Stephens Inc. AR purchased a new stake in Heron Therapeutics during the 4th quarter valued at $208,000.

In related news, Director John Poyhonen bought 3,000 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The stock was purchased at an average cost of $17.55 per share, with a total value of $52,650.00. Following the transaction, the director now owns 13,000 shares in the company, valued at approximately $228,150. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Waage Christian bought 1,400 shares of the company’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average cost of $18.04 per share, with a total value of $25,256.00. Following the completion of the transaction, the director now owns 1,400 shares in the company, valued at approximately $25,256. The disclosure for this purchase can be found here. Company insiders own 12.56% of the company’s stock.

NASDAQ:HRTX opened at $17.65 on Friday. Heron Therapeutics Inc has a 12 month low of $16.20 and a 12 month high of $42.90. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.40 and a quick ratio of 4.06. The stock has a market capitalization of $1.36 billion, a PE ratio of -7.23 and a beta of 1.61.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.30). Heron Therapeutics had a negative return on equity of 49.22% and a negative net margin of 194.43%. The company had revenue of $31.60 million during the quarter, compared to analysts’ expectations of $28.04 million. During the same period in the prior year, the business posted ($1.09) earnings per share. The company’s revenue for the quarter was up 172.4% on a year-over-year basis. As a group, research analysts forecast that Heron Therapeutics Inc will post -2.66 earnings per share for the current year.

Several brokerages have weighed in on HRTX. Zacks Investment Research cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 9th. Cantor Fitzgerald set a $50.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a research report on Friday, February 22nd. BidaskClub cut shares of Heron Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, March 27th. Northland Securities reissued a “buy” rating and set a $55.00 price target on shares of Heron Therapeutics in a research report on Thursday, May 9th. Finally, Cowen reissued a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, May 9th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $51.20.

TRADEMARK VIOLATION NOTICE: “California Public Employees Retirement System Sells 1,119 Shares of Heron Therapeutics Inc (NASDAQ:HRTX)” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://sportsperspectives.com/2019/06/14/california-public-employees-retirement-system-sells-1119-shares-of-heron-therapeutics-inc-nasdaqhrtx.html.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: Recession

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.